Vibeke Strand, MD, FACP, MACR
Adjunct Clinical Professor
Stanford University School of Medicine, Palo Alto CA
Portola Valley, CA, United States
Disclosure information not submitted.
Vivian Bykerk, MD, FRCPC
Hospital for Special Surgery
New York, NY, United States
Disclosure information not submitted.
Rheumatoid arthritis (RA) is a chronic inflammatory arthritis that can cause deformity, loss of function, and decreased quality of life. Since the 1990s, disease-modifying antirheumatic drugs (DMARDs) have been the foundation for RA treatment, initially with synthetic DMARDs and expanding thereafter to include biologic DMARDs and Janus kinase (JAK) inhibitors. JAK inhibitors have established efficacy in RA, but recent safety concerns associated with these drugs, such as an increased potential risk of cancer and cardiovascular events, have healthcare professionals (HCPs) and patients concerned about their use in RA. This program will include a robust discussion of the evidence-based application of recent efficacy and safety data for JAK inhibitors in RA to equip HCPs in helping patients attain low disease activity/remission and improved quality of life.
CCO designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Developed and offered by Clinical Care Options, LLC., and supported by Eli Lilly and Company
